Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2020)

Kymera Therapeutics (KYMR) has reported Treasury Shares for 8 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares rose 26.88% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 26.88% YoY), while the FY2025 annual figure was $1.3 million, up 79.45% from the prior year.
• Treasury Shares grew to $1.5 million in Q1 2026 per KYMR's latest filing, from $1.3 million in the prior quarter.
• Across five years, Treasury Shares topped out at $1.5 million in Q1 2026 and bottomed at $121504.0 in Q1 2022.
• Historically, Treasury Shares has averaged $746263.2 across 5 years, with a median of $636585.0 in 2024.
• Annual changes were most pronounced in 2022 — Treasury Shares surged 646.7% — and 2024, when it rose 26.38%.
• Kymera Therapeutics' Treasury Shares stood at $281843.0 in 2022, then jumped by 110.45% to $593140.0 in 2023, then rose by 26.38% to $749604.0 in 2024, then soared by 79.45% to $1.3 million in 2025, then advanced by 14.13% to $1.5 million in 2026.
• Business Quant data shows KYMR's Treasury Shares at $1.5 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.